Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Price History
|
Ratios
|
Insiders
Bullboard - Stock Discussion Forum
ABBOTT LABORATORIES
ABT
Healthcare
Medical Devices
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary...
spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrumen...
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Bullboard (NYSE:ABT)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Next
(33)
•••
SmartBull65
X
Post by
SmartBull65
on Nov 29, 2024 9:33am
ABT's Dividend + MYNZ Potential
ABT’s 50+ years of dividend growth make it a cornerstone for stability. Solid 1.7% yield, and I’m letting it compound. Meanwhile, keeping an eye on MYNZ—hearing chatter it could rocket soon. Anyone
...more
(1)
•••
ivosmith
X
Post by
ivosmith
on Nov 27, 2023 12:45am
Blood Gas and Electrolyte Analyzer Market Outlook 2023-2028
According to the latest research report, the global blood gas and electrolyte analyzer market size reached US$ 2.0 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 2.9
...more
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 29, 2022 7:05am
New Press Release - NOTICE For Investors In ABT: Lawsuit against Abbott Laboratories announced by Shareholders Foundation
San Diego, California--(Newsfile Corp. - November 29, 2022) - The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of Abbott Laboratories (NYSE: ABT).Investors who purchased Abbott Laboratories (NYSE: ABT) shares prior to February 2021 and continue...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 17, 2022 9:01am
New Press Release - Abbott Receives Three CES 2023 Innovation Awards for Advancements in Health Technology
The Consumer Technology Association (CTA) awards Abbott multiple CES 2023 Innovation Awards for industry-leading health technologiesAbbott's Aveir™ single-chamber (VR) leadless pacemaker, Proclaim™ Plus SCS system, Alinity® m Monkeypox PCR test honoredOther recent Abbott innovation honors include...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 31, 2022 3:11pm
New Press Release - ABT FINAL DEADLINE TODAY: ROSEN, A TOP RANKED LAW FIRM, Encourages Abbott Laboratories Investors to Secure Counsel Before Important October 31 Deadline in Securities Class Action - ABT
NEW YORK, Oct. 31, 2022 /PRNewswire/ --WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Abbott Laboratories (NYSE: ABT) between February 19, 2021 and June 8, 2022, both dates inclusive (the "Class Period"), of the important October 31, 2022 lead...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 31, 2022 12:41pm
New Press Release - ABT LAWSUIT ALERT: Levi & Korsinsky Notifies Abbott Laboratories Investors of a Class Action Lawsuit and Upcoming Deadline
New York, New York--(Newsfile Corp. - October 31, 2022) - Levi & Korsinsky, LLP notifies investors in Abbott Laboratories ("Abbott" or the "Company") (NYSE: ABT) of a class action securities lawsuit.The lawsuit on behalf of Abbott investors has been commenced in the the United States District...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 31, 2022 11:02am
New Press Release - Final Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Abbott Laboratories (ABT) Investors of Class Action and to Actively Participate
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Abbott Laboratories (“Abbott” or “the Company”) (NYSE: ABT) and certain of its officers, on behalf of all persons and entities that purchased, or otherwise acquired...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 31, 2022 5:45am
New Press Release - CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Abbott Investors of a Lead Plaintiff Deadline of October 31, 2022
NEW YORK, Oct. 31, 2022 /PRNewswire/ -- Attention Abbott Laboratories ("Abbott") (NYSE: ABT) shareholders:The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors. This lawsuit is on behalf of all persons or entities who purchased or otherwise...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 30, 2022 10:37am
New Press Release - Abbott Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 31, 2022 to Discuss Your Rights - ABT
New York, New York--(Newsfile Corp. - October 30, 2022) - Levi & Korsinsky, LLP notifies investors in Abbott Laboratories ("Abbott" or the "Company") (NYSE: ABT) of a class action securities lawsuit.The lawsuit on behalf of Abbott investors has been commenced in the the United States District...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 30, 2022 8:24am
New Press Release - Abbott Laboratories Deadline Alert
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Abbott Laboratories To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - October 30, 2022) - Faruqi & Faruqi, LLP, a leading national securities law...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 28, 2022 10:50pm
New Press Release - ABBOTT LABORATORIES 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Abbott Laboratories - ABT
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until October 31, 2022 to file lead plaintiff applications in a securities class action lawsuit against Abbott Laboratories (NYSE: ABT), if they...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 28, 2022 5:56pm
New Press Release - Abbott Laboratories Deadline Alert
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Abbott Laboratories To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - October 28, 2022) - Faruqi & Faruqi, LLP, a leading national securities law...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 28, 2022 9:00am
New Press Release - Abbott's FreeStyle Libre® is Named Best Medical Technology in Last 50 Years by the Galien Foundation
Abbott's FreeStyle Libre honored as the "best of the best" since 1970 during the Prix Galien Golden Jubilee AwardsRevolutionary FreeStyle Libre technology has transformed the lives of approximately 4.5 million people1 living with diabetes globallyABBOTT PARK, Ill., Oct. 28, 2022 /PRNewswire...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 28, 2022 5:46am
New Press Release - ABT SHAREHOLDER ALERT: Jakubowitz Law Reminds Abbott Shareholders of a Lead Plaintiff Deadline of October 31, 2022
NEW YORK, Oct. 28, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Abbott Laboratories (NYSE: ABT).To receive updates on the lawsuit, fill out the form: https://claimyourloss.com/securities/abbott...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 27, 2022 7:14pm
New Press Release - Abbott Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 31, 2022 to Discuss Your Rights - ABT
New York, New York--(Newsfile Corp. - October 27, 2022) - Levi & Korsinsky, LLP notifies investors in Abbott Laboratories ("Abbott" or the "Company") (NYSE: ABT) of a class action securities lawsuit.The lawsuit on behalf of Abbott investors has been commenced in the the United States District...
read article.
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.
Featured News Links
Desert Gold Advances Barani Gravity Plant Installation and Confirms Commissioning Target
Oregen Announces Board Changes and the Appointment of David French as Director
Podcasts